Products In 2012, dapagliflozin (Forxiga) was approved in the EU as the first agent in the new group of SGLT2 inhibitors. Several drugs are now on the market worldwide (see below). Structure and properties The SGLT2 inhibitors are derived from phlorizin, a -glucoside and natural substance first isolated from apple tree bark in 1835. Phlorizin … SGLT2 Inhibitor
Products The selective serotonin reuptake inhibitors (SSRIs) are mainly taken in the form of film-coated tablets or capsules. In addition, other dosage forms such as dispersible tablets, melting tablets and drops are available. Zimelidin was the first to be developed in the 1970s and was approved in the early 1980s. Sales had to be discontinued … Selective Serotonin Reuptake Inhibitor
Products Avibactam was approved in the United States in 2015, in the EU in 2016, and in many countries in 2019 in fixed combination with the cephalosporin ceftazidime as a powder for a concentrate for solution for infusion (Zavicefta). Structure and properties Avibactam (C7H11N3O6S, Mr = 265.25 g/mol), unlike other beta-lactamase inhibitors, is not itself … Avibactam
Products Deflazacort is commercially available in tablet form (Calcort). It has been approved in many countries since 1986. Structure and properties Deflazacort (C25H31NO6, Mr = 441.5 g/mol) differs from prednisolone in having an oxazoline ring at C16-C17. Effects Deflazacort (ATC H02AB13) has anti-inflammatory, antiallergic, and immunosuppressive properties. The mineralocorticoid effect of deflazacort is very low. … Deflazacort
Products Degarelix is commercially available as a powder and solvent for solution for injection (Firmagon). It was approved in many countries in February 2010. Structure and properties Degarelix is a decapeptide derived from gonadotropin-releasing hormone (GnRH), a hormone of the hypothalamus. It is present in drugs as degarelix acetate and differs from the natural substance … Degarelix
Products Alirocumab was approved in the United States in 2015 as the first agent in the group of PCSK9 inhibitors in the form of a solution for injection (Praluent). Evolocumab (Repatha) followed as the second agent in the EU, also in 2015. Structure and properties PCSK9 inhibitors to date are monoclonal antibodies that must be … PCSK9 Inhibitors
Products Dembrexin is commercially available as a powder for administration with feed as a veterinary drug. It has been approved in many countries since 1988. Structure and properties Dembrexin (C13H17Br2NO2, Mr = 379.1 g/mol) is a benzylamine. It is structurally closely related to bromhexine (e.g., bisolvone) and ambroxol (e.g., mucosolvone) and is present in the … Dembrexin
Products Citriodiol is commercially available in the form of sprays (e.g. Anti-Brumm Naturel, Anti-Brumm Tick Stop + Icaridin), among others. Structure and properties Citriodiol is produced from an extract of leaves of lemon eucalyptus, also called (family: Myrtaceae). A major active ingredient is -menthane-3,8-diol (PMD, C10H20O2, Mr = 172.3 g/mol). Effects Citriodiol protects between 6-8 … Citriodiol
Products Cladribine was approved for the treatment of multiple sclerosis in the EU in 2017 and in the United States and many countries in 2019 in tablet form (Mavenclad). Cladribine has also been commercially available as an infusion and injection solution in many countries since 1998 (Litak). This article relates to MS therapy. Structure and … Cladribine
Products Clascoterone was approved as a cream in the United States in 2020 (Winlevi). Structure and properties Clascoterone (C24H34O5, Mr = 402.5 g/mol) corresponds to the steroid cortexolone-17α-propionate. It exists as a white powder that is practically insoluble in water. Effects Clascoterone has antiandrogenic properties. The effects are due to antagonism at androgen receptors. Androgens … Clascoteron
Products Bumetanide was commercially available in tablet form (Burinex, off label). It was approved in many countries in 1974. Structure and properties Bumetanide (C17H20N2O5S, Mr = 364.4 g/mol) is a white crystalline powder that is practically insoluble in water. Effects Bumetanide (ATC C03CA02) is diuretic with rapid onset and short duration of action. Indications Oedema … Bumetanide
